Stockreport

Aptose Biosciences secures funds for AML treatment development [Yahoo! Finance]

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors
PDF Tuspetinib is an oral kinase inhibitor with potential as both a monotherapy and in combination therapies for newly diagnosed and relapsed or refractory AML patients. [Read more]